Seeking Alpha·Sep 15, 2026
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSTERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
STERIS is executing a disciplined operational playbook, evidenced by gross margin expansion from 40.2% in 2024Q4 to 45.8% in 2027Q1 and a dramatic reduction in leverage (D/E from 0.54 to 0.03). The company's recurring revenue base and strong cash conversion (O...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has accelerated to 7.3% in 2027Q1 with gross margin expanding 560 bps to 45.8%, while operating margin reached 19.1%.
STERIS plc has a 12-month price target of $275.20, representing a 36.3% upside, with a 2030 base case projection of $967.87 based on analyst consensus.
STERIS plc is recognized for its wide moat, indicating strong competitive advantages and barriers to entry in the healthcare and medical devices sector.
Top institutional holders like The Vanguard Group (12.07%) demonstrate strong confidence in STERIS plc's long-term growth potential.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $2.59+4.0% vs $2.49 | $1.5B+0.3% vs $1.5B |
Q2 2026 May 11, 2026 | $2.83-0.7% vs $2.85 | $1.6B-0.4% vs $1.6B |
Q1 2026 Feb 4, 2026 | $2.53+0.0% vs $2.53 | $1.5B+1.0% vs $1.5B |
Q4 2025 Nov 5, 2025 | $2.47+5.1% vs $2.35 | $1.5B+4.8% vs $1.4B |
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
Benchmark STE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for STERIS plc (STE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $209.98 | $20.46B | 26.48 | 8.73% | 13.23% | 11.37% | 1.17% | |
| $420.57 | $31.45B | 39.09 | 6.99% | 3.58% | 1.88% | — | |
| $87.07 | $5.19B | 40.88 | 11.66% | 9.22% | 9.07% | — | |
| $85.05 | $9.69B | 26.01 | 4.03% | 2.96% | 8.38% | — | |
| $15.53 | $1.21B | -2.31 | 1.53% | -0.44% | -0.69% | — | |
| $45.80 | $1.37B | 30.33 | 5.16% | 4.12% | 5.51% | — |
STERIS plc (STE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
STERIS plc (STE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 5, 2026·SEC
May 11, 2026·SEC
Get notified when STE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STERIS plc (STE) stock FAQ — growth, dividends, profitability & financials explained
STERIS plc (STE) reported $6.04B in revenue for fiscal year 2026. This represents a 927% increase from $587.9M in 1997.
STERIS plc (STE) grew revenue by 8.7% over the past year. This is steady growth.
Yes, STERIS plc (STE) is profitable, generating $805.1M in net income for fiscal year 2026 (13.2% net margin).
Yes, STERIS plc (STE) pays a dividend with a yield of 1.17%. This makes it attractive for income-focused investors.
STERIS plc (STE) has a return on equity (ROE) of 11.4%. This is reasonable for most industries.
STERIS plc (STE) generated $925.6M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
